Aidoc secures US$150m in series E funding

Aidoc has secured US$150m to expand its AI imaging platform and add new disease detection tools.

The company said the funding will support wider international adoption of its aiOS platform, which helps clinicians review medical scans and prioritise urgent cases. It also supports related tasks such as managing patient data.

Aidoc’s software is built around a custom foundation model called the Clinical AI Reasoning Engine, or CARE. The company said it can analyse medical images, electronic health results, patient vital signs and laboratory results.

A foundation model is a large AI system trained to work across several types of data, while vital signs are basic health measures such as pulse, breathing and blood pressure.

Aidoc said that the US Food and Drug Administration (FDA) cleared CARE in January for diagnostic tasks across 11 disease indicators, following earlier approvals covering three others.

Aidoc said the model can also identify incidentals, meaning possible disease indicators that doctors were not necessarily expecting to find in a scan.

After spotting an abnormality, the platform is designed to rank it by likely severity and alert medical teams through a mobile app.

The system also includes a spreadsheet-based interface for tracking patient status and identifying people who may be eligible for clinical trials.

Aidoc said its platform has been installed in nearly 2,000 hospitals worldwide and is used to process data relating to more than 60 million patients each year.

Goldman Sachs led the Series E round, with participation from Nvidia’s NVentures, General Catalyst and SoftBank Investment Advisors.

Aidoc said its total external funding has now passed US$500m.

The company plans to use the new capital to broaden international adoption of aiOS, expand CARE so it can detect more disease indicators, and develop a feature that drafts clinical reports from imaging data.

Aidoc said CARE has a specificity of up to 99.7 per cent, which means the chance of false positives is below 1 per cent.

The company added that its mean specificity is 98 per cent across the 11 disease indicators cleared in January.